Skip to main content
Clinical Trials/NCT00238914
NCT00238914CompletedPhase 2

Opiate Dependence: Combined Naltrexone/Behavior Therapy

New York State Psychiatric Institute1 site in 1 country12 target enrollmentStarted: August 1999Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
12
Locations
1
Primary Endpoint
Relapse to heroin addiction

Study Overview

Brief Summary

The overall goal of this research project is to test a newly developed behavioral therapy to enhance the efficacy of naltrexone maintenance and make it a viable alternative to methadone maintenance or detoxification methods for treatment of opiate dependence. HYPOTHESES:

  1. Outpatient treatment with Behavioral Naltrexone Therapy will yield a lower rate of relapse to illicit opiates compared to naltrexone plus Compliance Enhancement (CE) Therapy.
  2. Lifetime history of depression will predict dysphoria and non-compliance with naltrexone.

Detailed Description

Long-term maintenance on naltrexone has proven efficacy as a treatment for opiate dependence, but has not been successful clinically because of at least three problems: 1) The transition from opiate to naltrexone precipitates opiate withdrawal unless the patient has been off any opiates for at least seven days; 2) Compliance issues: patients can miss a few naltrexone doses and begin to experience effects from illicit opiates and become re-addicted, at which point naltrexone cannot be restarted without precipitating withdrawal; 3) Naltrexone may produce dysphoria in some patients. The proposed research study will offer opiate dependent patients brief hospitalization for a rapid detoxification from opiate to naltrexone, using buprenorphine, clonidine and clonazepam. If the patient has already undergone detoxification at an outside unit, they will be assessed for opiate dependence using the naloxone challenge. Patients will then be either discharged or entered directly into outpatient treatment where they will be randomly assigned to either the newly developed "Behavioral Naltrexone Therapy" (BNT), a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy or to Compliance Enhancement (CE) therapy, a controlled therapy intended to simulate outpatient psychiatric care. BNT employs behavioral incentives and enlists members of the family and social network to reinforce naltrexone compliance and abstinence. In this current investigation, for both BNT and CE, all patients are maintained on oral naltrexone. Patients are stratified at baseline by presence or absence of lifetime depressive disorder, which the investigators hypothesize will predict dysphoria on naltrexone and non-compliance. Patients are discharged from the hospital, or entered directly, into outpatient treatment at STARS at NYSPI to receive both counseling and Naltrexone, 50 mg per day.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

CE plus oral naltrexone

Active Comparator

Compliance enhancement plus oral naltrexone

Intervention: Naltrexone (Drug)

CE plus oral naltrexone

Active Comparator

Compliance enhancement plus oral naltrexone

Intervention: Compliance Enhancement (CE) (Behavioral)

BNT plus oral naltrexone

Active Comparator

Behavioral naltrexone therapy plus oral naltrexone

Intervention: Naltrexone (Drug)

BNT plus oral naltrexone

Active Comparator

Behavioral naltrexone therapy plus oral naltrexone

Intervention: Behavioral Naltrexone Therapy (BNT) (Behavioral)

Outcomes

Primary Outcomes

Relapse to heroin addiction

Time Frame: Up to 24 weeks or length of study participation

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Opiate Dependence: Combined... | Clinical Trial